|
|
 Purchase CD >> RNAi Europe
Formulations for Using Dicer-Substrate siRNA in vivo
Mark Behlke, Vice President, Molecular Genetics, Integrated DNA Technologies
Advanced RNAi Technology for Genome-Wide Screening
Bettina Haedrich, Global Product Manager Gene Silencing, QIAGEN
MISSIONTM RNAi: Using siRNA and shRNA to Mediate Gene Silencing
Heather Holemon, R&D Principle Investigator, Functional Genomics Group, Sigma-Aldrich
Targeting c-Jun and JunB Proteins as Potential Anti-Cancer Cell Therapy
Marta Izquierdo, Professor of Biochemistry and Molecular Biology, Autonomous University of Madrid
Targeting APP with Chemically Modified siRNA (stealthRNAi™) Ameliorates Alzheimer’s Disease
Neuropathology in a Transgenic Mouse Model
Xavier de Mollerat du Jeu, Scientist, Invitrogen
RNAi vs. K. O.: Phenotypic Comparison of shRNA-Expressing Animals and Knockout Mice Lacking
TRPV1
Jens Kurreck, Group Leader, Berlin Free University
High Throughput RNAi Screening: Initial Steps Toward Creation of a Functional Map of the
Human Genome
Devin Leake, Director of Research and Development, Thermo Fisher Scientific Dharmacon Products
The Silent Treatment: Delivering RNA Interference
Judy Lieberman, Senior Investigator, Harvard Medical School
Using siRNAs to Elucidate Gene Function: New Tools and Techniques
Susan Magdaleno, Manager, Scientists – RNAi, Ambion, An Applied Biosystems Business
Targeting of the RET/PTC1 Junction Oncogene in Papillary Thyroid Carcinoma by a siRNA
Reverses in-vitro and Inhibits in-vivo Tumoural Features
Claude Paul Malvy, Director, Institute for Higher Biomedical Studies (IFSBM)
Genome Wide Discovery of Various Classes of Small RNA Using the 454 Sequencing Technology
Peter Matthiesen, Global Marketing Director Genome Sequencing, Roche Applied Science
Making Therapeutic siRNA a Reality: Recent Advances in siRNA Manufacture
Paul McCormac, Director of Process and Analytical Development, Avecia Biotechnology
Genome-Wide Functional Analysis of Mitotic Genes in Live Human Cells Using RNAi in
Combination with Time-Lapse Microscopy
Beate Neumann, Scientist, European Molecular Biology Laboratory
RNAi Therapeutics Against Cancer
Takahiro Ochiya, Head, National Cancer Centre Research Institute
RNA Silencing in Prokaryotes
Volker Patzel, Group Leader, Max Planck Institute for Infection Biology
Delivery Methods for Gene Silencing Experiments
Teresa Rubio, Group Leader, Bio-Rad
Developing RNAi Therapeutics
Dmitry Samarsky, Vice President, Technology Development, RXi Pharmaceuticals
Reversible Gene Knockdown in Mice Using a Tight, Inducible shRNA Expression System
Jost Seibler, RNAi Group Leader, Artemis Pharmaceuticals
Combination of ckit Gene Silencing and Tocopherol Succinate: A Novel Therapy Against Human
Mast Cell Leukaemia
Irene Ruano Solana, PhD Student, Centro de Biología Molecular Severo Ochoa
Silencing HIV-1 with RNA Interference: A Multiple shRNA Approach
Karin von Eije, PhD Student, University of Amsterdam
LNA (Locked Nucleic Acid): Key Molecule Towards Realising Gene Silencing Drugs
Jesper Wengel, Professor, University of Southern Denmark
RNAi Intellectual Property Landscape
Kathleen Williams, Co-Chair Life Sciences Practice, Edwards Angell Palmer & Dodge
miRNA Symposium
Contribution of 3' UTR Features to the Functionality of miRNA Target Sites
Mihaela Zavolan, Professor, University of Basel
microRNAs in Animal Development and Human Cancer
Eric Miska, Cancer Research UK Senior Fellow, Wellcome Trust/Cancer Research UK Gurdon
microRNA Expression Profiling, Inhibition and High Content Screens
Stephanie Urschel, Field Application Scientist Europe, Thermo Fisher Scientific
What Can miRNAs Tell Us About Cancer?
Aimee Jackson, Senior Research Biologist/Research Fellow, Merck & Co/Rosetta Inpharmatics
RNA-Mediated Non-Mendalian Inheritance of Epigenetic Variations in the Mouse
Minoo Rassoulzadegan, Director Unit 636, INSERM, Université de Nice-Sophia Antipolis
Functional Genetic Approaches Identify Cancerous miRNAs
Reuven Agami, Associate Professor, Netherlands Cancer Institute
Toward a microRNA Revolution in the Cancer Society
George Calin, Associate Professor, University of Texas, MD Anderson Cancer Centre
The Cell Cycle Inhibitor p27kip1 is a Target of miR-221 and miR-222 in Prostate Carcinoma
Cell Lines
Silvia Anna Ciafrè, Associate Professor, University of Rome Tor Vergata
microRNA Expression in Gastrointestinal Cancer: Potential Implication in Clinical Research
Jesús García-Foncillas, Director, Department of Oncology and Pharmacogenomics Laboratory, University of Navarra
|
|
|